Who are Oruka Therapeutics, Inc.'s main suppliers?

Oruka Therapeutics, Inc. (ORKA) key suppliers include: CMOS, PARAGON, Halozyme Therapeutics, Inc., WUXI-BIOLOGICS-IRELAND-LIMITED, Jade Biosciences, Inc. and 2 more. View the full supplier network at chainsifter.com/chain/ORKA.

Who are Oruka Therapeutics, Inc.'s major customers?

Oruka Therapeutics, Inc. (ORKA) key customers include: MoonLake Immunotherapeutics, MoonLake Immunotherapeutics, Sanofi, Sanofi, PARAGON-THERAPEUTICS-INC and 2 more. View the full customer network at chainsifter.com/chain/ORKA.

What sector is Oruka Therapeutics, Inc. in?

Oruka Therapeutics, Inc. (ORKA) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Oruka Therapeutics, Inc. Suppliers, Customers & Supply Chain (ORKA)

7Suppliers

7Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Oruka Therapeutics, Inc. (ORKA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

18Total relationships

4Distinct source URLs

8High confidence

0.776Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Oruka Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CMOS	CMOS	92%	we currently rely on CMOs to manufacture our product candidates
PARAGON	PARAGON	90%	Pursuant to the terms of each of the License Agreements, we are obligated to pay Paragon non-refundable milestone payments of up to $12.0 million under each respective agreement upon the achievement …
HALO	Halozyme Therapeutics, Inc.	85%	Reciprocal relationship from HALO graph: Reciprocal relationship from ORKA graph: Reciprocal relationship from HALO graph: Reciprocal relationship from ORKA graph: Reciprocal relationship from HALO g…
WUXI-BIOLOGICS-IRELAND-LIMITED	WUXI-BIOLOGICS-IRELAND-LIMITED	80%	In consideration for the license, we agreed to pay WuXi Biologics a non-refundable milestone payment of up to $1.5 million upon the achievement of certain development milestones.
JBIO	Jade Biosciences, Inc.	72%	Reciprocal relationship from JBIO graph: Reciprocal relationship from ORKA graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from ORKA graph: Reciprocal relationship from JBIO g…
MLTX	MoonLake Immunotherapeutics	72%	ant to license agreements with Paragon. If the patent applications mature into one or more issued patents covering ORKA-001 or ORKA-002, we would expect those patents to expire in 2045, absent any ap…
MLTX	MoonLake Immunotherapeutics	72%	Reciprocal relationship from MLTX graph: Reciprocal relationship from ORKA graph: ant to license agreements with Paragon. If the patent applications mature into one or more issued patents covering OR…

Oruka Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
MLTX	MoonLake Immunotherapeutics	72%	Reciprocal relationship from MLTX graph: Reciprocal relationship from ORKA graph: Reciprocal relationship from MLTX graph: Reciprocal relationship from ORKA graph: Reciprocal relationship from MLTX g…
MLTX	MoonLake Immunotherapeutics	72%	ant to license agreements with Paragon. If the patent applications mature into one or more issued patents covering ORKA-001 or ORKA-002, we would expect those patents to expire in 2045, absent any ap…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from ORKA graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ORKA graph: proval, the period of time during…
SNYNF	Sanofi	72%	proval, the period of time during which we could market our product candidates under patent protection would be reduced. Thus, the patents that we may own and license may not afford us any meaningful…
PARAGON-THERAPEUTICS-INC	PARAGON-THERAPEUTICS-INC	62%	ses: (a) the Merger was treated as the equivalent of Pre-Merger Oruka issuing stock to acquire the net assets of ARCA, and (b) the reported historical operating results of the combined company prior …
PARUKA-HOLDING-LLC	PARUKA-HOLDING-LLC	62%	Certain patent rights covering ORKA-001 are expected to expire in 2045, absent any applicable patent term adjustments or extensions. Patent rights relating to ORKA-002, if issued, are also expected t…
WUXI-BIOLOGICS-IRELAND-LIMITED	WUXI-BIOLOGICS-IRELAND-LIMITED	62%	Certain patent rights covering ORKA-001 are expected to expire in 2045, absent any applicable patent term adjustments or extensions. Patent rights relating to ORKA-002, if issued, are also expected t…

Oruka Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
ORKA-DEBT	Debt stack $1.8M	90%	Market cache reports total debt of $1.8M.
ORKA-DEBT-11591	Warrants outstanding: 315356	90%	xbrl warrant detail from xbrl 2025-12-31.
ORKA-DEBT-11592	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2024-12-31.

Oruka Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Oruka Therapeutics, Inc..

Oruka Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
ORKA-OWNER-FMR-LLC	FMR LLC	90%	13F overlay lists FMR LLC as top holder; 188 tracked holders.

Oruka Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
CTMX	CytomX Therapeutics, Inc.	100.00	2
REGN	Regeneron Pharmaceuticals, Inc.	100.00	2
CALC	CalciMedica, Inc.	100.00	2
AMPH	Amphastar Pharmaceuticals, Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
CLYM	Climb Bio, Inc.	100.00	2
ATOS	Atossa Therapeutics, Inc.	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
AZN	AstraZeneca PLC	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
DBVTF	DBV TECHNOLOGIES	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
GRDX	GridAI Technologies Corp.	100.00	2

Oruka Therapeutics, Inc. Supply Chain